By Sarina Isaacs
Shares of Krystal Biotech slid after the company's first-quarter earnings missed Wall Street expectations.
The stock was down 14% at $139.03, putting shares 11% in the red for the year.
The Pittsburgh company on Tuesday reported a first-quarter profit of $35.7 million, or $1.20 a share, up from $932,000, or 3 cents a share, in the same quarter a year earlier. That fell short of the analyst consensus for $1.43 a share, according to FactSet.
Revenue nearly doubled to $88.2 million from the prior year's $45.3 million, but that also missed analyst estimates of $96.2 million.
The company said it ended the quarter with $765.3 million in cash and investments.
Krystal's signature product is Vyjuvek, a topical gene-therapy treatment used to treat wounds arising from genetic skin condition dystrophic epidermolysis bullosa.
Write to Sarina Isaacs at sarina.isaacs@wsj.com
(END) Dow Jones Newswires
May 06, 2025 12:05 ET (16:05 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。